Glenmark Pharmaceuticals has launched Thiazolidinedione Lobeglitazone (Lobeglitazone) in India for the treatment of type 2 diabetes in adults. Marketed under the brand name LOBG; it contains Lobeglitazone (0.5 mg) and to be taken once daily under prescription to improve glycemic control in adult diabetic patients.

Indians have a high prevalence of insulin resistance and that makes LOBG an appealing treatment option in managing uncontrolled Type 2 diabetes among insulin‐resistant diabetic patients.

Glenmark earlier received approval from the Drug Controller General of India for manufacturing and marketing Lobeglitazone based on a randomised, double‐blind Phase 3 clinical trial conducted on adult Type 2 diabetic patients, aged 18 years and older. The results of this trial have shown a faster and improved glycemic control with Lobeglitazone.

According to IQVIA sales data for the 12‐month period ending Aug 2022, the market for oral anti‐diabetic drugs in India is estimated to be Rs 11,725 crore. with an annual growth of 7% against the corresponding period last year (MAT Aug 2021). As per the International Diabetes Federation (IDF), the prevalence of diabetes in India is expected to increase to 125 million by 2045. Out of these, 77% of patients have uncontrolled diabetes. Moreover every four out of ten diabetic patients seem to have insulin resistance in India.